A Mandatory Rebranding: Lunai Bioworks Emerges from Enochian’s Ashes

The biotech firm formerly known as Enochian Biosciences has initiated a court-mandated corporate overhaul, emerging under the new identity of Lunai Bioworks Inc. This fundamental shift, formally enacted through a legal name change filed on November 3, 2025, represents a strategic effort to sever ties with the severe allegations surrounding co-founder Serhat Gumrukçu. The co-founder faced serious legal challenges, including charges related to an alleged murder-for-hire plot and accusations of fabricating critical research data.

Central to this corporate reset is a $2.5 million settlement, which received judicial approval on August 20, 2025. This resolution addresses investor claims that the company misled them concerning its corporate leadership and the validity of its scientific assertions.

Eligible investors are those who purchased Enochian Biosciences common stock between January 17, 2018, and June 27, 2022. The deadline for submitting a claim is December 7, 2025. A court hearing to finalize the settlement arrangement is scheduled for November 25, 2025.

Court-Ordered Governance Overhaul

As a condition of settling the shareholder litigation, the company's leadership has committed to a comprehensive series of corporate governance reforms. These measures, also filed in the California federal court on November 3, are designed to "enhance corporate value, improve business prospects, and restore investor confidence in the accuracy of the company's disclosures."

The key structural changes include:
- The appointment of an independent director to streamline board operations
- Implementation of a regular performance review process for the Chief Executive Officer
- The establishment of new protocols for audit and compensation committees
- Creation of a dedicated disclosure committee

Should investors sell immediately? Or is it worth buying Enochian Biosciences?

For investors seeking vetted opportunities within the pharmaceutical and biotech sectors, the complimentary premium report "5 Top Stocks 2025" offers five analyzed selections, including companies with promising oncology pipelines. ****

Prospects for a Successful Turnaround

This extensive restructuring is a direct consequence of a catastrophic erosion of trust, triggered by the revelations about its co-founder and a damning 2022 report from Hindenburg Research. These events precipitated a dramatic collapse in the company's share price.

For current stakeholders, the practical implications of the rebranding raise questions. While some financial data sources may still reference the company as Enochian Biosciences (ENOB), the ENOB ticker symbol is potentially obsolete, and the stock may face delisting. The company's scientific focus remains on preclinical treatments for HIV, Hepatitis B, and various cancers.

The pivotal uncertainty remains: Will a new name and a revised governance framework be sufficient to regain shattered investor confidence? The upcoming court dates and the deadline for investor claims will provide the first concrete indicators of whether this compulsory new beginning can ultimately succeed.